Journal
TRENDS IN IMMUNOLOGY
Volume 29, Issue 9, Pages 429-435Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2008.06.005
Keywords
-
Categories
Funding
- National Institutes of Health
- George and Mary Treadwell Foundation
- Arthritis Foundation
- Arthritis National Foundation
- ExCell Therapeutics
Ask authors/readers for more resources
Foxp3(+) CD4(+) CD25(+) regulatory cell (Treg) subsets that maintain immunologic homeostasis have been considered to be a homogeneous population of naturally occurring, thymus-derived CD4(+)CD25(+) cells (nTregs). However, similar Foxp3+ Tregs can be induced from CD25(-) precursors in vivo, and ex vivo with interleukin 2 (IL-2) and transforming growth factor beta (TGF-beta) (iTregs). These two subsets differ in their principal antigen specificities and in the T-cell receptor signal strength and co-stimulatory requirements needed for their generation. However, whether iTregs have any unique functions in vivo has been unclear. Although IL-6 can convert nTregs to Th17 cells, iTregs induced by IL-2 and TGF-beta are resistant to this cytokine and thereby might retain suppressive function at inflammatory sites. Thus, nTregs and iTregs may have different roles in the adaptive immune response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available